CDKN2A and cancer: Ma et al. [11] carried out a pan-cancer genome study and transcriptomic analysis on 1,699 pediatric patients with leukemia and solid tumors, and they found that the somatic alterations are mainly found at the level of TP53, KRAS (KRAS Proto-Oncogene, GTPase), NRAS (NRAS Proto-Oncogene, GTPase), CDKN2A (Cyclin Dependent Kinase Inhibitor 2A), or NOTCH1 (Notch Receptor 1) [11].